middle.news
Prescient Therapeutics Launches PTX-100 Phase 2 Trial After FDA Clearance
9:55am on Friday 31st of January, 2025 AEDT
•
Healthcare
Read Story
Prescient Therapeutics Launches PTX-100 Phase 2 Trial After FDA Clearance
9:55am on Friday 31st of January, 2025 AEDT
Key Points
FDA clears IND application for PTX-100 Phase 2 trial in r/r CTCL
Cash reserves stand at $8.4 million as of December 2024
Received $3.7 million R&D Tax Incentive Rebate in January 2025
Advancements in CellPryme and OmniCAR platforms with growing partner interest
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE